VIDEO: ‘Important’ interim results from CaboPoint trial

ByMoshe Ornstein, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

SAN FRANCISCO — In this video, Moshe Ornstein, MD, discusses interim results from the CaboPoint study presented at the annual ASCO Genitourinary Cancers Symposium.

The prospective phase 2 study investigated the use of cabozantinib (Cabometyx, Exelixis) following checkpoint inhibitor therapy among patients with advanced stage metastatic renal cell carcinoma, according to the abstract.

“Dr. Laurence Albiges presented, what I thought was, a really important study for clinical practice,” Ornstein, genitourinary medical oncologist at Cleveland Clinic Taussig Cancer Institute, said.

Reference:

Albiges L, et al. Abstract 606. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Ornstein reports serving as a consultant or in an advisory role for Aveo, Bristol Myers Squibb, Eisai, Exelixis, Merck and Pfizer; serving on speakers bureaus for Bristol Myers Squibb and Merck; receiving institutional research funding from Aravive, Astra-Zeneca, Astellas, Bristol Myers Squibb, Merck, Pfizer and Surface Oncology; and receiving reimbursement for travel and accommodations expenses from Bristol Myers Squibb, Eisai, Exelixis and Pfizer.

Take Homes in Renal Cell Carcinoma

Read more

VIDEO: ‘Important’ interim results from CaboPoint trial

Reference:

Related Content